产品信息 >> 蛋白相关 >> 重组蛋白;
Recombinant Human Vascular Endothelial Growth Factor C , C-6His, Human cells

产品描述

概述

Recombinant Human Vascular Endothelial Growth Factor C is produced by our Mammalian expression system and the target gene encoding Phe32-Arg227 is expressed with a 6His tag at the C-terminus.

使用说明

This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

技术规格

TagC-6His
种属Human
表达系统Human cells
Accession#P49767
SourceHuman Cells
Formulation_DescriptionLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 8.0.
StorageLyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months.
ReconstitutionDissolve the lyophilized protein in distilled water.
PurityGreater than 95% as determined by reducing SDS-PAGE.
EndotoxinLess than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
BackgroundVascular Endothelial Growth Factor (VEGF)-C is a member of the VEGF family, a group of polypeptide growth factors which play key roles in the physiology and pathology of many aspects of the cardiovascular system, including vasculogenesis, hematopoiesis, angiogenesis and vascular permeability. While VEGFC is homologous to other members of the VEGF/PDGF family, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF signalling in endothelial cells occurs through three tyrosine kinase receptors (VEGFRs) expressed by endothelial cells and hematopoietic precursors, and VEGF-C is a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. It is indicated that VEGFC undergoes a complex proteolytic maturation generating a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Knockout of the VEGF-C gene is embryonic lethal late in development, and although cells differentiate into the lymphatic lineage, they fail to sprout and form lymphatic vessels. Inactivation of a single VEGF-C allele results in the development of cutaneous lymphatic hypoplasia and lymphedema.
上一篇:Recombinant Human Va
下一篇:Recombinant Human Va
关于我们 | 产品信息 | 技术服务 | 联系我们

     电话:400-832-8698    地址:北京怀柔雁栖开发区光织谷东区二号楼 

   备案/许可证编号京ICP备2020036913号